Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,507.15
(
0.45%
)
US TECH 100
29,110.40
(
1.42%
)
Dow Jones
50,432.67
(
-0.29%
)
Brent Oil
96.86
(
-4.27%
)
Bitcoin
75,911.84
(
-1.76%
)
News Focus
News Focus
Post# of 257632
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123013
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 141170

Friday, 05/04/2012 1:04:50 PM

Friday, May 04, 2012 1:04:50 PM

Post# of 257632
1Q12 Botox vs Dysport worldwide sales in all indications…

• Botox: $415M, +7% YoY (http://finance.yahoo.com/news/allergan-4q-profit-climbs-6-192546492.html ).

• Dysport: $76M (€57.4M), +14% YoY (http://finance.yahoo.com/news/ipsens-first-quarter-2012-sales-050000770.html ). The above figures includes Ipsen’s sales of Dysport to MRX for the US cosmetic market and sales of Azzalure (an alias of Dysport) to Galderma for the European cosmetic market.

Thus, Botox had an 85% worldwide share of Botox+Dysport sales in 1Q12, which is consistent with AGN’s claim that Botox had a 76% overall share of the worldwide market for botulinum toxins in 4Q11 (#msg-75107630).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today